Last updated on June 2019

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)


Brief description of study

The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.

The secondary objectives of the study are:

  • To evaluate the effect of alirocumab Q2W on other lipid parameters (ie, apolipoprotein [Apo] A-1 and B, non-high-density lipoprotein cholesterol [non-HDL-C], total-cholesterol [TC], proportion of participants with 15%, 30%, and 50% LDL-C reductions, Lp(a), HDL-C, triglycerides [TG]) in participants with HoFH
  • To evaluate the safety and tolerability of alirocumab SC Q2W in participants with HoFH
  • To assess the pharmacokinetics of alirocumab SC Q2W in participants with HoFH
  • To assess the potential development of anti-drug (alirocumab) antibodies

Clinical Study Identifier: NCT03156621

Find a site near you

Start Over